Related Experiment Videos
Intravenous cysteamine therapy for nephropathic cystinosis
W A Gahl1, J Ingelfinger, P Mohan
1Section on Human Biochemical Genetics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1830, USA.
Pediatric Research
|October 1, 1995
Summary
Intravenous cysteamine effectively reduced leukocyte cystine levels in a child with nephropathic cystinosis. This treatment offers a promising approach for managing cystine accumulation in patients with this rare genetic disorder.
Area of Science:
- Biochemistry
- Pediatric Nephrology
- Pharmacology
Background:
- Nephropathic cystinosis is a rare genetic disorder characterized by lysosomal accumulation of cystine.
- Gastrointestinal dysmotility is a common complication, often with an unknown etiology.
- Cysteamine is a known therapeutic agent for cystinosis, but its efficacy via intravenous administration in pediatric patients requires further investigation.
Observation:
- A 4-year-old boy with nephropathic cystinosis and gastrointestinal dysmotility received intravenous cysteamine for 10 months.
- Leukocyte cystine levels were significantly reduced following cysteamine administration.
- Plasma cysteamine concentrations and dimethylsulfide levels were monitored throughout the treatment period.
Findings:
- Intravenous cysteamine effectively lowered leukocyte cystine levels from 11.9 to 1.1 nmol of half-cystine/mg of protein.
- The treatment demonstrated dose-dependent efficacy, with higher doses achieving greater cystine depletion.
- Oral cysteamine over a previous 3-year period achieved similar cystine reduction, suggesting comparable efficacy between routes.
Implications:
- Intravenous cysteamine administration is an effective method for reducing leukocyte cystine levels in pediatric patients with nephropathic cystinosis.
- This route of administration may be particularly beneficial for patients with severe gastrointestinal issues.
- Further research is warranted to optimize dosing and assess long-term outcomes and adverse effects of intravenous cysteamine therapy.